Literature DB >> 19185485

PI 3-kinase and cancer: changing accents.

Peter K Vogt1, Marco Gymnopoulos, Jonathan R Hart.   

Abstract

Research on PI 3-kinase (PI3K) is undergoing significant shifts in emphasis. Questions that have been dormant for some time are coming to the forefront, such as the relationship of PTEN to PI3K and the role of AKT in PI3K-driven oncogenesis. Two non-alpha isoforms of Class I PI3K are now established as important determinants in cancer: p110beta and p110delta. The oncogenic activities of p110beta include a non-catalytic function, a finding that will have immediate consequences for drug development.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19185485      PMCID： PMC2746202          DOI： 10.1016/j.gde.2008.11.011

Source DB:  PubMed          Journal:  Curr Opin Genet Dev        ISSN： 0959-437X            Impact factor:   5.578


  39 in total

Review 1.  The phosphatidylinositol 3-Kinase AKT pathway in human cancer.

Authors:  Igor Vivanco; Charles L Sawyers
Journal:  Nat Rev Cancer       Date:  2002-07       Impact factor: 60.716

2.  Essential, nonredundant role for the phosphoinositide 3-kinase p110delta in signaling by the B-cell receptor complex.

Authors:  Shiann-Tarng Jou; Nick Carpino; Yutaka Takahashi; Roland Piekorz; Jyh-Rong Chao; Neena Carpino; Demin Wang; James N Ihle
Journal:  Mol Cell Biol       Date:  2002-12       Impact factor: 4.272

Review 3.  Targeting phosphoinositide 3-kinase: moving towards therapy.

Authors:  Romina Marone; Vladimir Cmiljanovic; Bernd Giese; Matthias P Wymann
Journal:  Biochim Biophys Acta       Date:  2007-10-12

4.  Phosphoinositide 3-kinase p110beta activity: key role in metabolism and mammary gland cancer but not development.

Authors:  Elisa Ciraolo; Manuela Iezzi; Romina Marone; Stefano Marengo; Claudia Curcio; Carlotta Costa; Ornella Azzolino; Cristiano Gonella; Cristina Rubinetto; Haiyan Wu; Walter Dastrù; Erica L Martin; Lorenzo Silengo; Fiorella Altruda; Emilia Turco; Letizia Lanzetti; Piero Musiani; Thomas Rückle; Christian Rommel; Jonathan M Backer; Guido Forni; Matthias P Wymann; Emilio Hirsch
Journal:  Sci Signal       Date:  2008-09-09       Impact factor: 8.192

Review 5.  PI3K pathway alterations in cancer: variations on a theme.

Authors:  T L Yuan; L C Cantley
Journal:  Oncogene       Date:  2008-09-18       Impact factor: 9.867

Review 6.  The role of PTEN signaling perturbations in cancer and in targeted therapy.

Authors:  M Keniry; R Parsons
Journal:  Oncogene       Date:  2008-09-18       Impact factor: 9.867

7.  The PTEN-PI3K pathway: of feedbacks and cross-talks.

Authors:  A Carracedo; P P Pandolfi
Journal:  Oncogene       Date:  2008-09-18       Impact factor: 9.867

8.  Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis.

Authors:  Shidong Jia; Zhenning Liu; Sen Zhang; Pixu Liu; Lei Zhang; Sang Hyun Lee; Jing Zhang; Sabina Signoretti; Massimo Loda; Thomas M Roberts; Jean J Zhao
Journal:  Nature       Date:  2008-06-25       Impact factor: 49.962

9.  PTEN-deficient cancers depend on PIK3CB.

Authors:  Susan Wee; Dmitri Wiederschain; Sauveur-Michel Maira; Alice Loo; Christine Miller; Rosalie deBeaumont; Frank Stegmeier; Yung-Mae Yao; Christoph Lengauer
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-28       Impact factor: 11.205

10.  Isoform-specific functions of phosphoinositide 3-kinases: p110 delta but not p110 gamma promotes optimal allergic responses in vivo.

Authors:  Khaled Ali; Montserrat Camps; Wayne P Pearce; Hong Ji; Thomas Rückle; Nicolas Kuehn; Christian Pasquali; Christian Chabert; Christian Rommel; Bart Vanhaesebroeck
Journal:  J Immunol       Date:  2008-02-15       Impact factor: 5.422
View more
  39 in total

1.  MicroRNA-92a functions as an oncogene in colorectal cancer by targeting PTEN.

Authors:  Guangjun Zhang; He Zhou; Huaxu Xiao; Zuoliang Liu; Hongpeng Tian; Tong Zhou
Journal:  Dig Dis Sci       Date:  2013-09-12       Impact factor: 3.199

Review 2.  Drugging the PI3 kinome: from chemical tools to drugs in the clinic.

Authors:  Paul Workman; Paul A Clarke; Florence I Raynaud; Rob L M van Montfort
Journal:  Cancer Res       Date:  2010-02-23       Impact factor: 12.701

3.  VEGFR-2 expression in carcinoid cancer cells and its role in tumor growth and metastasis.

Authors:  Scott R Silva; Kanika A Bowen; Piotr G Rychahou; Lindsey N Jackson; Heidi L Weiss; Eun Y Lee; Courtney M Townsend; B Mark Evers
Journal:  Int J Cancer       Date:  2011-03-01       Impact factor: 7.396

Review 4.  Will kinase inhibitors make it as glioblastoma drugs?

Authors:  Ingo K Mellinghoff; Nikolaus Schultz; Paul S Mischel; Timothy F Cloughesy
Journal:  Curr Top Microbiol Immunol       Date:  2012       Impact factor: 4.291

5.  PI(3) kinases: revealing the delta lady.

Authors:  Paul Workman; Rob L M van Montfort
Journal:  Nat Chem Biol       Date:  2010-02       Impact factor: 15.040

6.  Role of phosphoinositide 3-OH kinase p110β in skeletal myogenesis.

Authors:  Ronald W Matheny; Melissa A Riddle-Kottke; Luis A Leandry; Christine M Lynch; Mary N Abdalla; Alyssa V Geddis; David R Piper; Jean J Zhao
Journal:  Mol Cell Biol       Date:  2015-01-20       Impact factor: 4.272

7.  microRNA-21 overexpression contributes to cell proliferation by targeting PTEN in endometrioid endometrial cancer.

Authors:  Xiaoyan Qin; Lei Yan; Xingbo Zhao; Chunyan Li; Yibing Fu
Journal:  Oncol Lett       Date:  2012-09-06       Impact factor: 2.967

8.  Spatially distinct roles of class Ia PI3K isoforms in the development and maintenance of PTEN hamartoma tumor syndrome.

Authors:  Qi Wang; Thanh Von; Roderick Bronson; Minzi Ruan; Wenxia Mu; Alan Huang; Sauveur-Michel Maira; Jean J Zhao
Journal:  Genes Dev       Date:  2013-07-15       Impact factor: 11.361

9.  PI3K p110 alpha and p110 beta have differential effects on Akt activation and protection against oxidative stress-induced apoptosis in myoblasts.

Authors:  R W Matheny; M L Adamo
Journal:  Cell Death Differ       Date:  2009-10-16       Impact factor: 15.828

10.  The role of autophagy in tumour development and cancer therapy.

Authors:  Mathias T Rosenfeldt; Kevin M Ryan
Journal:  Expert Rev Mol Med       Date:  2009-12-02       Impact factor: 5.600
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.